Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go wearable insulin delivery device in Australia and New Zealand. According to the terms of the agreement, AMSL Diabetes and NZMS Diabetes retain the right to promote, market and sell the V-Go device to clinics and […]
There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens – one for mealtime insulin and one for insulin throughout the day. But studies have found that people with Type II diabetes are willing to skip insulin injections if they have to […]
Valeritas (NSDQ:VLRX) has inked an exclusive distribution deal with Movi SpA for the commercialization of its V-Go wearable insulin delivery device in Italy. According to the terms of the deal, Movi will market and sell the V-Go device to diabetes clinics and patients in Italy, while Valeritas will remain responsible for the product’s development, regulatory approval […]
Valeritas (NSDQ:VLRX) said today that its V-Go wearable insulin delivery system is available in Puerto Rico. The Bridgewater, N.J.-based company has partnered with Fusion Consulting group to promote V-Go to Puerto Rico-based endocrinologists and general practitioners with Type II diabetes patients. Get the full story at our sister site, Drug Delivery Business News.
Valeritas (NSDQ:VLRX) touted positive findings today from an analysis of its V-Go wearable insulin delivery system with a weekly physician-driven insulin titration algorithm. Two-thirds of patients met their glycemic targets, the company said, and patient-reported hypoglycemia dropped by the end of the study. Get the full story at our sister site, Drug Delivery Business News.
Valeritas (NSDQ:VLRX) said today that it inked a deal with Aspire Capital Fund to buy $20 million of Valeritas’ common stock. According to the deal, Aspire Capital is slated to purchase common stock at Valeritas’ request from time to time during a 30-month period at prices based on the market price at the time of each […]
In a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump, Valeritas (NSDQ:VLRX) reported this week that use of its device led to a 44% reduction in total daily insulin dose per patient. A drastic cut to a patient’s daily insulin dose and improvement to their blood sugar levels […]
Insulin-delivery device maker Valeritas (NSDQ:VLRX) missed earnings and revenue expectations on Wall Street with its 1st quarter results. The Bridgewater, N.J.-based company pared its losses to -$11.9 million on sales of $4.6 million for the 3 months ended March 31, for bottom-line growth of 30% on sales loss of -8% compared with the same period last year. […]
Valeritas (NSDQ:VLRX) touted data today from a publication detailing the benefits of diabetes medication delivery devices, such as the company’s V-Go insulin delivery system. The article was published in the journal Managed Care. The Bridgewater, N.J.-based company’s V-Go device is a wearable, basal-bolus insulin delivery system for patients with Type II diabetes. Patients can administer a continuous, […]
Valeritas today priced its upcoming initial public offering, looking to raise $52.5 million through the sale of 5.25 million shares at $10 per share. The offering includes a 30-day underwriters option for the purchase of an additional 787,500 shares, which would take the total funding possible in the round to approximately $60 million. Bridgewater, N.J.-based Valeritas makes […]
Valeritas this week raised the stakes for its upcoming initial public offering, looking to raise $60 million by floating 6 million shares at between $9 and $11, up from an earlier hoped for $50 million. Bridgewater, N.J.-based Valeritas makes the V-Go basal insulin delivery system for Type II diabetes, a fully disposable, continuous-delivery device that’s designed to […]